Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK159802 dose-ascending crossover study in persistent asthma
2006-001891-19Phase 2Terminated
- Sponsor
- GSK
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK159802 in asthma (5 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in clinic visit trough pre-bronchodilator and pre-dose FEV1 after 14 days of repeat dosing. Started Jun 2006; status: terminated.
02
Drugs
GSK159802
03
Conditions
asthma
Beyond the preview
Go deeper on 2006-001891-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001891-19.